Prescription medicine
Hyaluronidase and ocrelizumab Brand names: Ocrevus
Hyaluronidase and ocrelizumab (Ocrevus) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the hyaluronidase and ocrelizumab FDA label on DailyMed (effective August 17, 2026); every hyaluronidase and ocrelizumab label on DailyMed.
Highlights of the record
FDA label of August 17, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageOCREVUS ZUNOVO is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults OCREVUS ZUNOVO is a CD20-directed cytolytic antibody indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome,
Forms and strengths
- 920 mg/23ml / 23ml
Injection (solution).
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
What is hyaluronidase and ocrelizumab used for?
From the label: indications and usageOCREVUS ZUNOVO is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults OCREVUS ZUNOVO is a CD20-directed cytolytic antibody indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 ) Primary progressive MS, in adults
FDA pharmacologic class: CD20-directed Cytolytic Antibody and Endoglycosidase.
Source: FDA drug label (Ocrevus Zunovo), Genentech, Inc., effective August 17, 2026 (SPL set b216af61-99d0-42a3-afc2-b5bf86df1ec0), via openFDA; the full label on DailyMed
What does the patient leaflet for hyaluronidase and ocrelizumab say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about OCREVUS ZUNOVO?OCREVUS ZUNOVO can cause serious side effects, including: Injection reactions: Injection reactions are a common side effect of OCREVUS ZUNOVO, which can be serious and may require you to be hospitalized. You will be monitored for signs and symptoms of an injection reaction when you receive OCREVUS ZUNOVO. This will happen during all injections, for at least 1 hour after your first injection, and for at least 15 minutes after all injections following the first injection. Tell your healthcare provider or nurse if you get any of these symptoms: itchy skin rash hives tiredness coughing or wheezing trouble breathing throat irritation or pain feeling faint fever redness on your face (flushing) nausea headache swelling of the throat dizziness injection site pain, swelling or redness shortness of breath fatigue fast heart beat These injection reactions can happen during or up to 24 hours after your injection. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each injection. Infection: Infections are a common side effect. OCREVUS ZUNOVO increases your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Serious infections can happen with OCREVUS ZUNOVO, which can be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, or a cough that does not go away, or painful urination. […]
Source: FDA drug label (Ocrevus Zunovo), Genentech, Inc., effective August 17, 2026 (SPL set b216af61-99d0-42a3-afc2-b5bf86df1ec0), via openFDA; the full label on DailyMed
Is there a generic for hyaluronidase and ocrelizumab (Ocrevus)?
No generic hyaluronidase and ocrelizumab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the hyaluronidase and ocrelizumab label say about other medicines?
The hyaluronidase and ocrelizumab label names 8 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Acetaminophen | warnings and precautions | The addition of an antipyretic (e.g., acetaminophen) may also be considered [see Dosage and Administration (2.3) ]. |
| Dexamethasone | warnings and precautions | Reducing the Risk of Injection Reactions and Managing Injection Reactions Administer oral premedication (e.g., dexamethasone or an equivalent corticosteroid, and an antihistamine) at least 30 minutes prior to each OCREVUS ZUNOVO injection to reduce the risk of injection reactions. |
| Fingolimod | drug interactions | When switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, consider the duration and mode of action of these drugs because of additive immunosuppressive effects when initiating OCREVUS ZUNOVO [see Warnings and Precautions (5.2) ]. |
| Interferon beta 1a | warnings and precautions | Breast cancer occurred in 6 of 781 females treated with intravenous ocrelizumab and none of 668 females treated with REBIF or placebo. |
| Methylprednisolone | warnings and precautions | In MS clinical trials where ocrelizumab was administered intravenously, the incidence of infusion reactions in patients [who received methylprednisolone (or an equivalent steroid) and possibly other premedication to reduce the risk of infusion reactions prior to infusion] was 34% to 40%, with the highest incidence … |
| Mitoxantrone | drug interactions | When switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, consider the duration and mode of action of these drugs because of additive immunosuppressive effects when initiating OCREVUS ZUNOVO [see Warnings and Precautions (5.2) ]. |
| Natalizumab | drug interactions | When switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, consider the duration and mode of action of these drugs because of additive immunosuppressive effects when initiating OCREVUS ZUNOVO [see Warnings and Precautions (5.2) ]. |
| Teriflunomide | drug interactions | When switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, consider the duration and mode of action of these drugs because of additive immunosuppressive effects when initiating OCREVUS ZUNOVO [see Warnings and Precautions (5.2) ]. |
Source: FDA drug label (Ocrevus Zunovo), Genentech, Inc., effective August 17, 2026 (SPL set b216af61-99d0-42a3-afc2-b5bf86df1ec0), via openFDA; the full label on DailyMed
What next?
- Other cd20-directed cytolytic antibodys
- the pharmacologic class, with prices and generics
- Check an interaction
- what two or more labels say about each other